Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$29.67 - $60.28 $801,090 - $1.63 Million
-27,000 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$59.27 - $95.73 $177,810 - $287,190
-3,000 Reduced 10.0%
27,000 $1.6 Million
Q1 2021

May 14, 2021

SELL
$72.16 - $117.4 $721,600 - $1.17 Million
-10,000 Reduced 25.0%
30,000 $2.47 Million
Q4 2020

Feb 16, 2021

SELL
$38.09 - $100.95 $761,800 - $2.02 Million
-20,000 Reduced 33.33%
40,000 $3.64 Million
Q1 2020

May 14, 2020

SELL
$17.28 - $31.88 $172,800 - $318,800
-10,000 Reduced 14.29%
60,000 $1.33 Million
Q3 2018

Nov 14, 2018

BUY
$8.75 - $16.29 $175,000 - $325,800
20,000 Added 40.0%
70,000 $1.14 Million
Q2 2018

Aug 13, 2018

BUY
$9.16 - $13.48 $458,000 - $674,000
50,000 New
50,000 $567,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $202M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Altrinsic Global Advisors LLC Portfolio

Follow Altrinsic Global Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altrinsic Global Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Altrinsic Global Advisors LLC with notifications on news.